Logo image of ALCOX.PA

NICOX SA (ALCOX.PA) Stock Fundamental Analysis

EPA:ALCOX - Euronext Paris - Matif - FR0013018124 - Common Stock - Currency: EUR

0.2315  +0 (+2.03%)

Fundamental Rating

2

ALCOX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. ALCOX may be in some trouble as it scores bad on both profitability and health. ALCOX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALCOX had negative earnings in the past year.
ALCOX had a negative operating cash flow in the past year.
In the past 5 years ALCOX always reported negative net income.
In the past 5 years ALCOX always reported negative operating cash flow.
ALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFALCOX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -21.10%, ALCOX is in line with its industry, outperforming 59.15% of the companies in the same industry.
With a Return On Equity value of -38.13%, ALCOX perfoms like the industry average, outperforming 57.75% of the companies in the same industry.
Industry RankSector Rank
ROA -21.1%
ROE -38.13%
ROIC N/A
ROA(3y)-35.8%
ROA(5y)-26.67%
ROE(3y)-69.46%
ROE(5y)-48.73%
ROIC(3y)N/A
ROIC(5y)N/A
ALCOX.PA Yearly ROA, ROE, ROICALCOX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALCOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCOX.PA Yearly Profit, Operating, Gross MarginsALCOX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

ALCOX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCOX has about the same amout of shares outstanding than it did 1 year ago.
ALCOX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALCOX is higher compared to a year ago.
ALCOX.PA Yearly Shares OutstandingALCOX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ALCOX.PA Yearly Total Debt VS Total AssetsALCOX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -9.66, we must say that ALCOX is in the distress zone and has some risk of bankruptcy.
ALCOX has a worse Altman-Z score (-9.66) than 74.65% of its industry peers.
ALCOX has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.40, ALCOX perfoms like the industry average, outperforming 57.75% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -9.66
ROIC/WACCN/A
WACC7.17%
ALCOX.PA Yearly LT Debt VS Equity VS FCFALCOX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

ALCOX has a Current Ratio of 2.57. This indicates that ALCOX is financially healthy and has no problem in meeting its short term obligations.
ALCOX has a Current ratio of 2.57. This is comparable to the rest of the industry: ALCOX outperforms 54.93% of its industry peers.
ALCOX has a Quick Ratio of 2.57. This indicates that ALCOX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALCOX (2.57) is better than 63.38% of its industry peers.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.57
ALCOX.PA Yearly Current Assets VS Current LiabilitesALCOX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.16% over the past year.
Looking at the last year, ALCOX shows a very negative growth in Revenue. The Revenue has decreased by -51.31% in the last year.
The Revenue has been growing by 11.38% on average over the past years. This is quite good.
EPS 1Y (TTM)70.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)-51.31%
Revenue growth 3Y-18.83%
Revenue growth 5Y11.38%
Sales Q2Q%21.19%

3.2 Future

The Earnings Per Share is expected to grow by 14.86% on average over the next years. This is quite good.
The Revenue is expected to decrease by -41.42% on average over the next years. This is quite bad
EPS Next Y18.96%
EPS Next 2Y14.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.98%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALCOX.PA Yearly Revenue VS EstimatesALCOX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ALCOX.PA Yearly EPS VS EstimatesALCOX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCOX. In the last year negative earnings were reported.
Also next year ALCOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCOX.PA Price Earnings VS Forward Price EarningsALCOX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCOX.PA Per share dataALCOX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ALCOX's earnings are expected to grow with 14.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.86%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALCOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NICOX SA

EPA:ALCOX (5/8/2025, 7:00:00 PM)

0.2315

+0 (+2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-21 2025-04-21
Earnings (Next)07-16 2025-07-16
Inst Owners6.35%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap16.06M
Analysts84.44
Price Target1.02 (340.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-22.22%
Revenue NY rev (3m)-22.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.49
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.05
BVpS0.66
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.1%
ROE -38.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.8%
ROA(5y)-26.67%
ROE(3y)-69.46%
ROE(5y)-48.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.74%
Cap/Sales 2.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.57
Quick Ratio 2.57
Altman-Z -9.66
F-Score2
WACC7.17%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y18.96%
EPS Next 2Y14.86%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-51.31%
Revenue growth 3Y-18.83%
Revenue growth 5Y11.38%
Sales Q2Q%21.19%
Revenue Next Year3.98%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.36%
OCF growth 3YN/A
OCF growth 5YN/A